GlassScriptPhysician profile
Afshin Hamidi
NPI 1609222090
$698.24
in general payments reported to CMS, 2019-2025
11 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $191 · 2023: $143 · 2024: $104 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $150.53 | 2019-2023 | Omnipod |
| Recordati_rare_diseases_inc. | $136.98 | 2024-2025 | Isturisa, Signifor Lar |
| Becton, Dickinson and Company | $130.54 | 2022 | |
| Beta Bionics, INC. | $62.84 | 2024 | Ilet Bionic Pancreas |
| Abbvie INC. | $45.23 | 2023 | |
| Antares Pharma, INC. | $42.61 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Lilly USA, LLC | $39.41 | 2022 | |
| Allergan, INC. | $35.19 | 2019 | |
| Amgen INC. | $23.59 | 2025 | Tepezza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.14 | 2019 | |
| Tolmar, INC. | $15.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshin Hamidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.